Comparison of Platelet Aggregation Response in Switching Antiplatelet Therapy or Doses in Elder Patients After Coronary Stenting
Not Applicable
- Conditions
- Coronary Artery Disease
- Registration Number
- JPRN-UMIN000029541
- Lead Sponsor
- Juntendo University Graduate School of Medicine Department of Cardiovascular Medicine
- Brief Summary
Switching from clopidogrel 75 mg to prasugrel 2.5 mg significantly lowered and aggregated the PRU value. Whereas, dose reduction of prasugrel had a significantly lower proportion of bleeding risk over one year after PCI than the continuation of prasugrel 3.75 mg, and was an independent predictor for bleeding risk with reference of continuation of prasugrel 3.75 mg.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 400
Inclusion Criteria
Not provided
Exclusion Criteria
1 Patients who survive within 1 year 2 Patients who are indicated for revascularization such as percutaneous coronary intervention or bypass 3 Patients who are judged inappropriate inthis trial by director
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change of PR
- Secondary Outcome Measures
Name Time Method Death Cardiovascular event Bleeding event (ISTH major bleeding)